TY - JOUR
T1 - New technologies in tumor ablation
AU - Singla, Nirmish
AU - Gahan, Jeffrey
N1 - Publisher Copyright:
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2016
Y1 - 2016
N2 - Purpose of review: The application of ablative modalities for small renal masses continues to increase. In addition, multiple technologies continue to be studied for the treatment of these renal masses. This review focuses on new and emerging technologies so that the clinician can become more familiar with these modalities as they become available in clinical practice. Recent findings Radiofrequency ablation (RFA) and cryoablation (cryo) continue to be the most often used ablative modalities for the treatment of small renal masses. In addition, they are the most thoroughly studied modalities leading to a set of well defined variables predicting successful ablation. Microwave ablation (MWA) and irreversible electroporation are newer modalities that offer theoretical advantages to RFA and cryo, although each differs in the specific advantage provided. Multiple animal studies have been performed with each modality; however, in both cases, the optimal device settings are not well defined. For MWA in particular, there are a significant number of systems available and within each system, there are an array of variables that can be modified, which influences the ablation zone size and shape. Other emerging technologies include stereotactic body radiation and high-intensity focused ultrasound, although each has limited data supporting their efficacy to date. Summary Ablation technology continues to multiply and evolve. Newer technologies such as MWA and irreversible electroporation are promising as they offer theoretical advantages to RFA and cryo. However, both require further studies to identify the optimal tumor characteristics and device settings leading to successful ablation.
AB - Purpose of review: The application of ablative modalities for small renal masses continues to increase. In addition, multiple technologies continue to be studied for the treatment of these renal masses. This review focuses on new and emerging technologies so that the clinician can become more familiar with these modalities as they become available in clinical practice. Recent findings Radiofrequency ablation (RFA) and cryoablation (cryo) continue to be the most often used ablative modalities for the treatment of small renal masses. In addition, they are the most thoroughly studied modalities leading to a set of well defined variables predicting successful ablation. Microwave ablation (MWA) and irreversible electroporation are newer modalities that offer theoretical advantages to RFA and cryo, although each differs in the specific advantage provided. Multiple animal studies have been performed with each modality; however, in both cases, the optimal device settings are not well defined. For MWA in particular, there are a significant number of systems available and within each system, there are an array of variables that can be modified, which influences the ablation zone size and shape. Other emerging technologies include stereotactic body radiation and high-intensity focused ultrasound, although each has limited data supporting their efficacy to date. Summary Ablation technology continues to multiply and evolve. Newer technologies such as MWA and irreversible electroporation are promising as they offer theoretical advantages to RFA and cryo. However, both require further studies to identify the optimal tumor characteristics and device settings leading to successful ablation.
KW - High-intensity focused ultrasound ablation
KW - Irreversible electroporation
KW - Kidney
KW - Microwave ablation
KW - Stereotactic ablative body radiation
UR - http://www.scopus.com/inward/record.url?scp=84960461878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960461878&partnerID=8YFLogxK
U2 - 10.1097/MOU.0000000000000284
DO - 10.1097/MOU.0000000000000284
M3 - Review article
C2 - 26967263
AN - SCOPUS:84960461878
VL - 26
SP - 248
EP - 253
JO - Current Opinion in Urology
JF - Current Opinion in Urology
SN - 0963-0643
IS - 3
ER -